Navigation Links
Eric K. Rowinsky Joins ADVENTRX Board of Directors
Date:2/25/2008

al and preclinical investigations which led to the development of paclitaxel, docetaxel, topotecan, irinotecan, erlotinib and gefitinib, among others.

Dr. Rowinsky is the Editor-in-Chief of Investigational New Drugs, an Associate Editor and/or Editorial Board Member of Cancer Research (Associate Editor and Reviews Editor), Clinical Cancer Research, Annals of Oncology, Cancer Biology and Therapy and several other oncology journals and has published over 270 manuscripts in both the preclinical and clinical research fields. He has also served on the Scientific Advisory Board and Project Advisory Boards of a large number of pharmaceutical and biotechnology companies and has advised and/or presented aspects of New Drug Applications to the FDA on several occasions. Dr. Rowinsky's honors include receipt of the career development award of the American Cancer Society and the 6th Annual Emil J. Freireich Award for outstanding achievement of a young researcher in clinical cancer therapeutics. He also served on the Board of Scientific Counselors of the National Cancer Institute.

Dr. Rowinsky received his B.A. degree from New York University and his M.D. from the Vanderbilt University School of Medicine. Following his residency in internal medicine at the University of California, he completed fellowship training in medical oncology at the Johns Hopkins University School of Medicine.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases. The Company seeks to improve the performance and safety of existing treatments by addressing significant problems such as drug metabolism, bioavailability, excessive toxicity and treatment resistance. More information can be found on the Company's web site at http://www.adventrx.com.

Forward Loo
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
2. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
3. Hank Plain Joins Morgenthaler Ventures as Partner
4. Legendary Earvin Magic Johnson Joins AFL/Signalife Cardiovascular Protection Team
5. Senior Research Analyst Richard Evans Joins AVOS Life Sciences
6. Dan Broderick Joins Prolog Ventures as Partner
7. Ingenuity Systems Joins Biomarkers Consortium
8. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
9. Glycominds Joins Biomolecular Photonic (BMP) Consortium to Develop New Molecular Imaging Technique
10. Progeniq Joins Microsoft in Bio IT Alliance
11. Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...PRNewswire-FirstCall/ -- BioSpecifics Technologies...ny developing first-in-class collagenase-based pro...he third quarter ended September 30, 2009. ,, ...s year, the FDA,s Arthritis Advisory Committee una...val of XIAFLEX(TM) for the treatment of Dupuytren,...
(Date:11/6/2009)...ov. 6 Calbiotech, Inc. announced t...ovative Research (SBIR) Phase I contract by the U....er terms of the agreement, Calbiotech will develop...s of Dengue virus. ,, Dengue virus is a mosq...t to military forces deployed to tropical areas of...
(Date:11/5/2009)...5 GenVec, Inc. (Nasdaq: ...the third quarter ended September 30, 2009. GenVec...are) for the three months ended September 30, 2009... share) in the comparable quarter of 2008. For the...t loss was $14.1 million ($0.15 per share), compar...
(Date:11/5/2009)...day, November 5, 2009 at 4:30 p.m. Eastern Time ,...FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("Onc...eported unaudited financial results for the third ...nd reviewed the Company,s highlights for the third... results reflect the operations of OncoGenex Techn...
Breaking Biology Technology:Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 6Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8
...s., Oct. 31 Idenix,Pharmaceuticals, Inc., (Nasdaq...financial results for the third quarter of 2007 on... markets close. In conjunction with the issuance ...a conference call at 4:30 p.m. ET on Tuesday, Nove...sults for the third quarter,2007. To access the c...
...ct. 31 Modigene Inc. (OTC,Bulletin Board: MODG) t...,at the Acumen BioFin Rodman & Renshaw 9th Annual ...07 at 1:40 pm ET. The conference will be held at,t...ne CEO Abraham Havron and President Shai Novik wil...ew and review of corporate,developments. The pres...
.... 31 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS )...n,BioFin(TM) Rodman & Renshaw 9th Annual Healthcar...p.m. EST (1:25 p.m. PST). The conference is being,... Ph.D., President and Chief Executive Officer of A...ew of Anadys and its two,development-stage product...
Other Biology Technology:Modigene to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference 2
(Date:11/4/2009)...,, CARLSBAD, Calif., Oct. 23 Ge...ure biosample management for genomic discovery, me...vid Wellis, Ph.D., GenVault,s President and CEO, w...e taking place on October 26th and 27th in La Joll...ill provide an overview of the company together wi...
(Date:11/4/2009)...,, NEW YORK, Oct. 27 Global Rai...mpany and advanced R&D laboratory, today annou...e and is prepared to actively commercialize its su...dge biometric security offerings. ,, During the...llions of dollars to develop and deploy a series o...
(Date:11/4/2009)...,, CARLSBAD, Calif., Nov. 4 Gen...hat William Brody, M.D., Ph.D., has joined its Boa...idential Chair of the Salk Institute, is an acclai...ior to joining the Salk Institute, Dr. Brody serve...e is a member of the National Academy of Engineeri...
Breaking Biology News(10 mins):GenVault Corporation to Present at the 2009 BIOCOM Investor Conference 2Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 2Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 3Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 3Secretary Shinseki Moves to Simplify PTSD Compensation Rules 55136 1Secretary Shinseki Moves to Simplify PTSD Compensation Rules 55136 2Grammy 28R 29 Nominated R 26B Sensation Angie Stone Teams up With the American Diabetes Association to Encourage African Americans to be Victorious in 55133 1Grammy 28R 29 Nominated R 26B Sensation Angie Stone Teams up With the American Diabetes Association to Encourage African Americans to be Victorious in 55133 2Grammy 28R 29 Nominated R 26B Sensation Angie Stone Teams up With the American Diabetes Association to Encourage African Americans to be Victorious in 55133 3Grammy 28R 29 Nominated R 26B Sensation Angie Stone Teams up With the American Diabetes Association to Encourage African Americans to be Victorious in 55133 4IDEV 28R 29 Technologies Announces First Patient Enrolled in Multi Center Clinical Trial of SUPERA 28R 29 PERipheral Stent 4886 1IDEV 28R 29 Technologies Announces First Patient Enrolled in Multi Center Clinical Trial of SUPERA 28R 29 PERipheral Stent 4886 2
...mall molecules containing platinum, Virginia Commo...s have created a process to inhibit a class of pro...may help researchers develop new drugs to fight HI...n as zinc fingers. , In the May 30 issue of the j...ed that a zinc finger protein, known as HIV NCp7, ...
...earcher Zafira Castaño has discovered that the los...favors tumor growth. This was the conclusion that ...tion which she defended at the University of Navar...h prior studies from her laboratory, which demonst...cells that coat the normal lung, and which, nevert...
...ty crayfish - a voracious, bullying exotic that ha...akes - may have finally met its match. , Since it... 1950s, the crayfish has spread to thousands of la...sts that are critical fish habitat, evicting the n...r and scooping up fish eggs like so much caviar. ...
Other Biology News:New protein target may advance design of HIV and cancer drugs 2Study shows hope for ridding lakes of clawed invader 2Study shows hope for ridding lakes of clawed invader 3
...lasma Immunodepletion Kit specifically removes 20 ... serum in preparation for further proteomics analy...o the plasma proteome whether you use one- or two-...ional chromatography or go straight to mass spectr...
...ntroduced the industry's first siRNA sequence desi... keep these tools consistent with new experimental...field of RNAi. With the introduction of our new, ...ine is pleased to offer the most significant advan...
... Signal Enhancer does for enzyme-/substrate-based ...ive blotting it increases the signal up to 10-fol... ,The Western Blot Signal Enhancer membrane treat...added to your current Western blotting protocol. ...
pYES2/CT from Invitrogen
Biology Products: